InvestEU

Delivering on the InvestEU Fund

Reykiavik, 10th January 2024
THE EIB GROUP

The lending arm of the European Union since 1958

Specialist provider of risk finance to small and medium-sized enterprises
EIB AT A GLANCE

Largest multilateral lender and borrower in the world

- We raise our funds on the international capital markets.
- We pass on favourable borrowing conditions to clients.

Over €1.5 trillion invested since 1958

- More than 14,900 projects in over 160 countries.
- Crowding-in bank: €4.9 trillion overall investment mobilised.

Headquartered in Luxembourg

- Around 4,020 staff: In addition to finance professionals, we have engineers, economists and socio-environmental experts.
- 59 offices around the world.
EIB & ICELAND

EUR 1.2bn signed

23 Operations Signed

Public Policy Goals

• Sustainable cities and regions
• Sustainable energy and natural resources
• SMEs and Mid-Caps
<table>
<thead>
<tr>
<th>EU in 2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Investment gap in key policy areas</td>
</tr>
<tr>
<td>High risk characteristics of operations in</td>
</tr>
<tr>
<td>key policy areas</td>
</tr>
<tr>
<td>Limited public resources and persistent investment</td>
</tr>
<tr>
<td>barriers</td>
</tr>
<tr>
<td>COVID 19 crisis</td>
</tr>
<tr>
<td>... and since</td>
</tr>
<tr>
<td>Economic Impact of COVID 19 and Russian invasion of</td>
</tr>
<tr>
<td>Ukraine</td>
</tr>
</tbody>
</table>
Mobilise investment

- InvestEU Fund

Advise on investment opportunities

- European Investment Advisory Hub
- European Investment Project Portal

Create investment friendly environment

- Structural reforms
- Improving the regulatory environment

To create policy impact for

- Sustainable Infrastructure
- Research, Innovation and Digitalisation
- Small and Medium Enterprises
- Social Investment and Skills
Single “umbrella” mandate for operations in the EU, Norway and Island for the Multiannual Financial Framework 2021-2027

EU Budgetary guarantee of EUR 26.2 bn
EIBG granted 75%; i.e. EUR 19.6 bn

Different compartments: EU and Member States compartment
Different implementing partners: EIBG, NPBIs/Multilaterals

Important policy focus
Narrower theme-based approach

Dedicated Steering Board, Advisory Board and Investment Committee (supported by dedicated EC Secretariats)
**InvestEU - Making a difference to the economy**

---

### Additionality – Value Added

<table>
<thead>
<tr>
<th>Addressing market failures and related sub-optimal investment situations</th>
<th>Reaching new clients</th>
<th>Absorbing more risk and maximising co-investments</th>
</tr>
</thead>
</table>

### Impact

<table>
<thead>
<tr>
<th>Social</th>
<th>Economic</th>
<th>Climate and Environmental</th>
</tr>
</thead>
</table>
The 4 Policy Windows under InvestEU

**SUSTAINABLE INFRASTRUCTURE**
Projects in sustainable energy, digital connectivity, transport, circular economy, water, waste and other environment Infrastructure, etc.

**RESEARCH, INNOVATION AND DIGITISATION**
Projects in research and innovation, technology transfer to market, digitization of industry, artificial intelligence, etc.

**SMALL BUSINESSES**
Projects facilitating access to finance for SMEs and small mid-caps.

**SOCIAL INVESTMENT AND SKILLS**
Projects in training, social housing, schools, universities, hospitals, social innovation, microfinance, social enterprise, integration of immigrants, refugees and vulnerable people, etc.

EUR 9.9 bn

EUR 6.6 bn

EUR 6.9 bn

EUR 2.8 bn
InvestEU – Role of the EIB Group

EIB will focus on three Policy Windows (SIW, RIDW and SISW).

EIF will also contribute to the three Policy Windows (SIW, RIDW and SISW) and in addition, cater towards the SMEW.

The EIBG contribution is higher to the RIDW window and lower to the SISW, compared to the overall 75% share.
**Sustainable Infrastructure**

**Sustainable Transport**
- Connecting Infrastructure TEN-T
- Cleaner Safe and Smart Mobility

**Clean Energy Transition**
- Decarbonized energy networks and generation
- Energy efficiency
- Other low carbon network infrastructure

**Environment and Resources**
- Clean water
- Circular economy
- Natural ecosystems

**Digital Connectivity**
- Sustainable Gigabit Networks & 5G
- Sustainable Data infrastructures
- Backbone networks of strategic importance

**Space Infrastructure; Tourism; Bioeconomy; Modernisation and Decarbonisation of Industry; Investment in Green Assets; Blue Economy**

**Research, Innovation and Digitalisation**

**European Green Deal Innovations**
- Energy
- Modernisation and decarbonisation of industry
- Sustainable and smart transport and mobility
- Circular economy
- Bioeconomy
- Sustainable Blue Economy
- Nature-based solutions, natural capital and ecosystem restoration
- Adaptation to climate change
- Innovative solutions for environmental observations and climate services
- Sustainable ICT

**Health**
- Clinical development, validation and market entry, focusing on areas of unmet medical and public needs for vaccination, therapeutics & diagnostics
- Strengthening the research, testing, development and implementation of innovative solutions relevant for the transformation of health and care systems

**Strategic Technologies**
- Clean water
- Circular economy
- Natural ecosystems

**Defence Investments in Dual Use; Research and Technology Infrastructures, Organizations and Universities; Nuclear Research**
**InvestEU EIB Project Cycle**

**STEP 1** 
Proposal

Project promoters present proposal to EIB directly

**STEP 2** 
EIB Appraisal

- financial
- economic
- social
- environmental
- and technical assessment

**STEP 3** 
EIB Approval

- EIB Management Committee
- Investment Committee assessment and approval
- Final approval by EIB Board of Directors

**STEP 4** 
Signature

Financing contract is agreed

**STEP 5** 
Disbursement

**STEP 6** 
Monitoring and reporting

**STEP 7** 
Repayment

**InvestEU PROJECT CYCLE**
InvestEU project selection and eligibility criteria

Projects need to:

<table>
<thead>
<tr>
<th><strong>EIB selection criteria</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>be commercially sound, economically and technically viable</td>
</tr>
<tr>
<td>support EU priorities</td>
</tr>
<tr>
<td>be mature enough to be bankable</td>
</tr>
<tr>
<td>be within EU, Norway or Island</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Additional InvestEU eligibility criteria</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>address market failures or sub-optimal investment situation</td>
</tr>
<tr>
<td>need to be additional</td>
</tr>
<tr>
<td>achieve a multiplier effect and where possible crowd-in private investment</td>
</tr>
<tr>
<td>help meet EU policy objectives</td>
</tr>
</tbody>
</table>
### EIB offer under InvestEU

- **Direct InvestEU transactions** – while bankable in principle – allow the Bank to facilitate or accelerate projects by pushing certain boundaries beyond EIB standards: (i) maturity, (ii) subordination, (iii) less collateral,…

- **Indirect InvestEU transactions** aim to share risks with banks and other intermediaries in order to allow them to directly engage in eligible IEU transactions.

---

**Financial Intermediary**

- Corporate / MidCap
- Venture Debt
- Project Finance
- Public Sector/ PPP
- Smaller Final Recipients (e.g. SMEs, municipalities,…)
Thank you!

For further questions: info@eib.org
Affibody is a Swedish company that has developed a unique technology platform enabling them to build a broad pipeline of drug candidates for diseases with high unmet medical needs. Affibody molecules have properties that enable high drug efficacy, patient-friendly administration options, and which reduce the risk of immune reactions.

Affibody has a proven ability to establish collaborations with other companies in order to reduce the Company’s development costs and maximise the potential for successful global market introductions, which include EUR 100m of revenues to date.

Development of innovative next generation multi-specifics biologics based targeting unmet medical needs in immunology and oncology indications.
P-CAM DEMONSTRATION CONSTRUCTION PLANT

Amount: EUR 36.7m
Sector: Critical Raw Materials/Circular Economy
Country: Germany
Signed: 2 December 2022

Investment rationale:
• supports the deployment of an innovative manufacturing process, which reduces the carbon footprint, improves safety and reduces the cost of manufacturing
• contributes to the establishment of the EU’s battery value chain
• enhances the supply security of a critical raw material (Cobalt)
• supports the implementation of the EU’s climate objectives

• EUR 36.7m of venture debt to KOENIGSWARTER & EBELL CHEMISCHE FABRIK GMBH a German company wholly owned by Pure Battery Technologies Germany AG, which is a 100% subsidiary of Pure Battery Technologies Ltd.

• The venture debt financing is supporting a demonstration project worth EUR 73.5m in total:
  ▶ The Borrower plans to convert an established nickel production facility (brownfield) into its first commercial-scale demonstration facility for pCAM production. This is the preliminary stage of the cathode active material (“CAM”) used in the production of lithium-ion (“Li-ion”) batteries; it is crucial to the battery manufacturing supply chain.
  ▶ The PBT process can use a mixed feedstock of both 1) intermediate metal products (e.g. MHP) and 2) Black Mass (battery material processed for recycling) as feedstock.
**ICOSAGEN**

**Investment rationale:**

- Well-positioned technology to succeed in the CDMO business
- Good potential on the market
- Reputable investors base
- State-of-the-art technology that lead to develop robust relationships with leading pharmaceutical companies and world-class academic leaders

Icosagen AS is an Estonian biotech developing innovative solutions in the discovery, development and manufacturing of biopharmaceuticals. It was founded in 1999 to provide molecular diagnostics services to Estonian medical institutions. It provides contract research services to the biopharma / biotech industries and academia to support the development of biologic drugs. Icosagen offers a catalogue of off-the-shelf products, such as antibodies, proteins, and ELISA kits. Icosagen numbers c. 100 employees and caters its products and services to academic, biopharmaceutical and biotechnology industries.